Biotechnology
Compare Stocks
4 / 10Stock Comparison
DRTS vs IART vs NVCR vs MDT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Instruments & Supplies
Medical - Devices
DRTS vs IART vs NVCR vs MDT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Biotechnology | Medical - Devices | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $691M | $1.06B | $1.92B | $99.94B |
| Revenue (TTM) | $0.00 | $1.64B | $674M | $35.48B |
| Net Income (TTM) | $-43M | $-496M | $-173M | $4.61B |
| Gross Margin | — | 39.6% | 75.2% | 61.9% |
| Operating Margin | — | 5.8% | -27.2% | 17.9% |
| Forward P/E | — | 5.8x | — | 14.1x |
| Total Debt | $14M | $2.03B | $290M | $28.52B |
| Cash & Equiv. | $16M | $235M | $103M | $2.22B |
DRTS vs IART vs NVCR vs MDT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| Alpha Tau Medical L… (DRTS) | 100 | 81.3 | -18.7% |
| Integra LifeScience… (IART) | 100 | 19.6 | -80.4% |
| NovoCure Limited (NVCR) | 100 | 12.7 | -87.3% |
| Medtronic plc (MDT) | 100 | 66.0 | -34.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DRTS vs IART vs NVCR vs MDT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
DRTS is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.
- Lower volatility, beta 1.72, Low D/E 17.8%, current ratio 7.45x
- Beta 1.72, current ratio 7.45x
- +188.6% vs MDT's -2.8%
IART is the clearest fit if your priority is value.
- Lower P/E (5.8x vs 14.1x)
NVCR is the clearest fit if your priority is growth exposure.
- Rev growth 8.3%, EPS growth 21.8%, 3Y rev CAGR 6.8%
- 8.3% revenue growth vs DRTS's -115.8%
MDT carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 36 yrs, beta 0.47, yield 3.6%
- 26.5% 10Y total return vs DRTS's -22.3%
- 13.0% margin vs IART's -30.1%
- Beta 0.47 vs IART's 2.34, lower leverage
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 8.3% revenue growth vs DRTS's -115.8% | |
| Value | Lower P/E (5.8x vs 14.1x) | |
| Quality / Margins | 13.0% margin vs IART's -30.1% | |
| Stability / Safety | Beta 0.47 vs IART's 2.34, lower leverage | |
| Dividends | 3.6% yield; 36-year raise streak; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +188.6% vs MDT's -2.8% | |
| Efficiency (ROA) | 175.8% ROA vs DRTS's -42.3%, ROIC 6.0% vs -46.5% |
DRTS vs IART vs NVCR vs MDT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
DRTS vs IART vs NVCR vs MDT — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MDT leads in 3 of 6 categories
IART leads 1 • DRTS leads 1 • NVCR leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
MDT leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDT and DRTS operate at a comparable scale, with $35.5B and $0 in trailing revenue. MDT is the more profitable business, keeping 13.0% of every revenue dollar as net income compared to IART's -30.1%. On growth, NVCR holds the edge at +12.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $1.6B | $674M | $35.5B |
| EBITDAEarnings before interest/tax | $18M | $209M | -$165M | $9.4B |
| Net IncomeAfter-tax profit | -$43M | -$496M | -$173M | $4.6B |
| Free Cash FlowCash after capex | -$33M | -$10M | -$48M | $5.4B |
| Gross MarginGross profit ÷ Revenue | — | +39.6% | +75.2% | +61.9% |
| Operating MarginEBIT ÷ Revenue | — | +5.8% | -27.2% | +17.9% |
| Net MarginNet income ÷ Revenue | — | -30.1% | -25.7% | +13.0% |
| FCF MarginFCF ÷ Revenue | — | -0.6% | -7.1% | +15.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +2.4% | +12.3% | +8.8% |
| EPS Growth (YoY)Latest quarter vs prior year | 0.0% | +81.8% | -100.0% | -11.9% |
Valuation Metrics
IART leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, IART's 13.0x EV/EBITDA is more attractive than MDT's 14.3x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $691M | $1.1B | $1.9B | $99.9B |
| Enterprise ValueMkt cap + debt − cash | $689M | $2.9B | $2.1B | $126.2B |
| Trailing P/EPrice ÷ TTM EPS | -14.81x | -2.01x | -13.80x | 21.60x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 5.77x | — | 14.13x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 36.00x |
| EV / EBITDAEnterprise value multiple | — | 13.01x | — | 14.32x |
| Price / SalesMarket cap ÷ Revenue | — | 0.65x | 2.92x | 2.98x |
| Price / BookPrice ÷ Book value/share | 8.20x | 1.00x | 5.51x | 2.08x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 19.28x |
Profitability & Efficiency
MDT leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
MDT delivers a 9.4% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-57 for DRTS. DRTS carries lower financial leverage with a 0.18x debt-to-equity ratio, signaling a more conservative balance sheet compared to IART's 1.95x. On the Piotroski fundamental quality scale (0–9), MDT scores 6/9 vs DRTS's 3/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -57.3% | -47.6% | -50.8% | +9.4% |
| ROA (TTM)Return on assets | -42.3% | -13.7% | -16.5% | +175.8% |
| ROICReturn on invested capital | -46.5% | +1.7% | -16.4% | +6.0% |
| ROCEReturn on capital employed | -48.7% | +2.2% | -28.9% | +7.5% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.18x | 1.95x | 0.85x | 0.59x |
| Net DebtTotal debt minus cash | -$2M | $1.8B | $187M | $26.3B |
| Cash & Equiv.Liquid assets | $16M | $235M | $103M | $2.2B |
| Total DebtShort + long-term debt | $14M | $2.0B | $290M | $28.5B |
| Interest CoverageEBIT ÷ Interest expense | -100.93x | -10.36x | -96.80x | 9.08x |
Total Returns (Dividends Reinvested)
DRTS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DRTS five years ago would be worth $8,084 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, DRTS leads with a +188.6% total return vs MDT's -2.8%. The 3-year compound annual growth rate (CAGR) favors DRTS at 35.6% vs NVCR's -37.6% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +62.5% | +12.9% | +28.3% | -18.1% |
| 1-Year ReturnPast 12 months | +188.6% | +6.5% | +1.1% | -2.8% |
| 3-Year ReturnCumulative with dividends | +149.2% | -73.1% | -75.7% | -4.2% |
| 5-Year ReturnCumulative with dividends | -19.2% | -81.7% | -91.3% | -27.7% |
| 10-Year ReturnCumulative with dividends | -22.3% | -63.0% | +30.3% | +26.5% |
| CAGR (3Y)Annualised 3-year return | +35.6% | -35.4% | -37.6% | -1.4% |
Risk & Volatility
Evenly matched — DRTS and MDT each lead in 1 of 2 comparable metrics.
Risk & Volatility
MDT is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than IART's 2.34 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DRTS currently trades 86.5% from its 52-week high vs MDT's 73.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.72x | 2.34x | 2.20x | 0.47x |
| 52-Week HighHighest price in past year | $9.07 | $16.49 | $20.06 | $106.33 |
| 52-Week LowLowest price in past year | $2.57 | $8.70 | $9.82 | $77.16 |
| % of 52W HighCurrent price vs 52-week peak | +86.5% | +82.2% | +83.9% | +73.3% |
| RSI (14)Momentum oscillator 0–100 | 49.4 | 75.9 | 69.8 | 27.3 |
| Avg Volume (50D)Average daily shares traded | 328K | 858K | 1.5M | 7.8M |
Analyst Outlook
MDT leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: DRTS as "Buy", IART as "Buy", NVCR as "Buy", MDT as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs -11.5% for IART (target: $12). MDT is the only dividend payer here at 3.57% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $12.00 | $12.00 | $33.50 | $109.50 |
| # AnalystsCovering analysts | 4 | 26 | 15 | 49 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +3.6% |
| Dividend StreakConsecutive years of raises | — | 0 | — | 36 |
| Dividend / ShareAnnual DPS | — | — | — | $2.78 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.0% | 0.0% | +3.2% |
MDT leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). IART leads in 1 (Valuation Metrics). 1 tied.
DRTS vs IART vs NVCR vs MDT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is DRTS or IART or NVCR or MDT a better buy right now?
For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.
3% revenue growth year-over-year, versus 1. 5% for Integra LifeSciences Holdings Corporation (IART). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Alpha Tau Medical Ltd. (DRTS) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — DRTS or IART or NVCR or MDT?
On forward P/E, Integra LifeSciences Holdings Corporation is actually cheaper at 5.
8x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — DRTS or IART or NVCR or MDT?
Over the past 5 years, Alpha Tau Medical Ltd.
(DRTS) delivered a total return of -19. 2%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: NVCR returned +30. 3% versus IART's -63. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — DRTS or IART or NVCR or MDT?
By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.
47β versus Integra LifeSciences Holdings Corporation's 2. 34β — meaning IART is approximately 402% more volatile than MDT relative to the S&P 500. On balance sheet safety, Alpha Tau Medical Ltd. (DRTS) carries a lower debt/equity ratio of 18% versus 195% for Integra LifeSciences Holdings Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — DRTS or IART or NVCR or MDT?
By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.
3% versus 1. 5% for Integra LifeSciences Holdings Corporation (IART). On earnings-per-share growth, the picture is similar: Medtronic plc grew EPS 30. 8% year-over-year, compared to -73. 6% for Integra LifeSciences Holdings Corporation. Over a 3-year CAGR, NVCR leads at 6. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — DRTS or IART or NVCR or MDT?
Medtronic plc (MDT) is the more profitable company, earning 13.
9% net margin versus -31. 6% for Integra LifeSciences Holdings Corporation — meaning it keeps 13. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MDT leads at 17. 8% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is DRTS or IART or NVCR or MDT more undervalued right now?
On forward earnings alone, Integra LifeSciences Holdings Corporation (IART) trades at 5.
8x forward P/E versus 14. 1x for Medtronic plc — 8. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.
08Which pays a better dividend — DRTS or IART or NVCR or MDT?
In this comparison, MDT (3.
6% yield) pays a dividend. DRTS, IART, NVCR do not pay a meaningful dividend and should not be held primarily for income.
09Is DRTS or IART or NVCR or MDT better for a retirement portfolio?
For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
47), 3. 6% yield). Integra LifeSciences Holdings Corporation (IART) carries a higher beta of 2. 34 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +26. 5%, IART: -63. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between DRTS and IART and NVCR and MDT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: DRTS is a small-cap quality compounder stock; IART is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock. MDT pays a dividend while DRTS, IART, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.